September, 2021

article thumbnail

Potential new drug for incurable vascular dementia

Drug Discovery Today

A drug already used to treat high blood pressure could be re-purposed as the first treatment to tackle a type of vascular dementia caused by damaged and ‘leaky’ small blood vessels in the brain, according to research part-funded by the British Heart Foundation and published today in the Journal of Clinical Investigation.

Drugs 178
article thumbnail

Workshop and lecture on generic portfolio management

Drug Patent Watch

I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…. The post Workshop and lecture on generic portfolio management appeared first on DrugPatentWatch - Make Better Decisions.

90
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How CVS Health Drives Cardinal Health’s Distribution Financials

Drug Channels

Cardinal Health recently released the annual report for its 2021 fiscal year, which ended on June 30. See the links below. Today, I delve into the financials behind Cardinal’s relationship with its largest customer, CVS Health. In Cardinal’s 2021 fiscal year, CVS purchased more than $42 billion in pharmaceuticals from the wholesaler—about double the figure from 10 years ago.

article thumbnail

Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD

The Pharma Data

Survey of Over 1,000 Asthma and COPD Patients Conducted in Partnership with AAFA Finds Symptoms are Disruptive to Daily Lives for Majority of Respondents Despite Treatment Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Inhaler Tales – a national campaign aimed toward raising awareness about the role inhaler misuse may play in inadequate disease control.1.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Part 2 Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis - Recap

The Strateos Blog: Drug Discovery

On September 15th, Strateos hosted Part 2 of its Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis. In continued efforts to provide scientists with end-to-end technologies to accelerate their workflows, Strateos has expanded its synthetic chemistry solutions with the integration of PerkinElmer Informatics Signals™ electronic lab notebook (ELN).

article thumbnail

mRNA Vaccines – The promise of more to come

Tebu Bio: Drug Discovery

Propelled into the spotlight by the COVID-19 pandemic, mRNA has become a biological entity of great interest in drug discovery - yet mRNA vaccination is just the beginning of more and more discoveries and applications.

Vaccine 52

More Trending

article thumbnail

New patent for Glaxosmithkline drug ANORO ELLIPTA

Drug Patent Watch

Annual Drug Patent Expirations for ANORO+ELLIPTA Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are fourteen patents…. The post New patent for Glaxosmithkline drug ANORO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 82
article thumbnail

Drug Channels Update: Buy-and-Bill Market Trends (NEW Live Video Webinar)

Drug Channels

Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Friday, September 24, 2021, from 12:00 p.m. to 1:30 p.m. ET This page describes the event and explains how to purchase a registration. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series.

article thumbnail

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN

The Pharma Data

Extension analyses observed patients taking AJOVY experienced a reduction in migraine and headache days and evaluated disability and health-related quality of life. Online symposium to highlight healthcare and neurology disparities as a major public health issue and discuss the state of diversity in migraine clinical studies, barriers to recruitment, and the need for more inclusive and diverse studies.

article thumbnail

The Principles of Exempted Devices

Pharmaceutical Development Group

Introduction: Devices exempted under 510(k) state if the device offers safety and is highly effective on the consumers under the FDA. Exempted Devices which get relaxation by 510(k) are classified by the FDA into Class I type, Class II type, and Class III type. There are specific regulations mentioned with each generic type of device. The classification regulations, however, come over various categories of devices.

FDA 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

What is Pediatric Psoriasis?

Olympian Clinical Research

Affecting more than 3% of the United States population, psoriasis is a skin disorder that causes red, raised patches of skin covered with thick flakes. It can have a considerably negative impact on a person’s quality of life and psychological well-being. The patches typically appear on the elbows, knees or scalp. While it is most common in adults, a third of psoriasis cases can also be found in children, which is known as pediatric psoriasis. .

article thumbnail

Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly

Drug Discovery Today

Demand for Touchlight’s synthetic DNA vector has grown rapidly since last year.dbDNA™ is driving biomedical innovations such as DNA and mRNA vaccines, synthetic DNA-based neutralising antibody therapies, and more.Touchlight’s synthetic DNA vector is revolutionising genetic medicine manufacture by offering a superior alternative to traditional plasmid DNA.

DNA 113
article thumbnail

New patent expiration for Pfizer drug ZYVOX

Drug Patent Watch

Annual Drug Patent Expirations for ZYVOX Zyvox is a drug marketed by Pfizer and is included in three NDAs. It is available from four suppliers. There are two patents protecting…. The post New patent expiration for Pfizer drug ZYVOX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 81
article thumbnail

How Cigna’s Growing Pharmacy Platform Expands Its Channel Power (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from May 2021. Last week, Cigna released its earnings for the first quarter of 2021. Links below. I was struck by how quickly Cigna’s Express Scripts PBM business has increased revenues and prescriptions from its retail pharmacy network.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

World Rabies Day: Boehringer Ingelheim fights rabies misconceptions

The Pharma Data

Boehringer Ingelheim again joins efforts to fight rabies under this year’s theme for World Rabies Day by GARC: “Rabies: Facts, not Fear” Boehringer Ingelheim strives to raise awareness of the disease and its preventio. Today on World Rabies Day, we commemorate the death of Pasteur who developed the primary rabies vaccine, laying the foundations for rabies prevention.

Vaccine 52
article thumbnail

Similarity Search and Some Cool Pandas Tricks

Practical Cheminformatics

In this post, we're going to take a look at molecular similarity searches. Molecular similarity is central to a lot of what we do in Cheminformatics. It's important for identifying analogs and understanding SAR. Molecular similarity is also at the core of many clustering methods that we use to understand datasets or design screening libraries. In this example, we'll be using the chemfp package by Andrew Dalke.

article thumbnail

Living with OCD Tips

Olympian Clinical Research

Obsessive-compulsive disorder (OCD) is a common mental illness that affects people of all ages, races and genders. Individuals affected with this disorder often have trouble recognizing and managing their obsessive, recurring thoughts, which lead them to engage in compulsive and repetitive behaviors. Luckily, people with OCD can live full and complete lives with some simple OCD tips. .

article thumbnail

In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors

Crown Bioscience

In this post we explore the different in vitro potency assays for assessing the function of anti-PD-1 checkpoint inhibitors, which are used to test the T cell response of anti-PD-1 (programmed death-1) agents.

52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Which drugs have the most supplementary protection certificates?

Drug Patent Watch

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 79
article thumbnail

Available for Preorder: The 2021-22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

On October 5, 2021, Drug Channels Institute will release The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our twelfth edition— remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. We are providing you with the opportunity to preorder this thoroughly updated and revised 2021-22 edition at special discounted prices.

article thumbnail

Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options

The Pharma Data

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S. retail pharmacies Monthly prescriptions for all Lilly insulins — including Insulin Lispro Injection — remain available for $35 through the Lilly Insulin Value Progra

article thumbnail

Pathogen data in ChEMBL

The ChEMBL-og

Infectious disease is a leading cause of death globally and bioactivity data against pathogens (fungi, bacteria, viruses, and parasites) is an important category in ChEMBL, especially in light of the ongoing pandemic. In ChEMBL version 29, there are over 2 M bioactivity data points against fungal, bacterial or viral targets (for 460 K compounds) available for pathogen-related research.

article thumbnail

Latest news on drug repurposing in oncology #10

The Anticancer Fund

30 September 2021 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.

article thumbnail

Accelerating Cancer Drug Discovery with Digital Pathology-Based Biomarker Analysis

Crown Bioscience

Accelerating cancer drug discovery with digital pathology-based biomarker analysis is transforming the field of modern pathology.

Drugs 52
article thumbnail

Which pharmaceutical drugs have the most drug patents in Bulgaria?

Drug Patent Watch

This chart shows the drugs with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

How and Why I Was Overcharged by Penn Medicine and My Blue Cross Health Plan (A True Story)

Drug Channels

Sometimes, a little knowledge can be a bad thing. I want to share with you, dear reader, the strange but true tale of my recent foray into the wonderful world of hospital price transparency for routine lab services. I discovered—with great effort—that the rates my health plan negotiated with the largest local health system in Philadelphia were greater than the self-pay, cash price.

article thumbnail

FDA authorizes software that can help identify prostate cancer

The Pharma Data

Today, the U.S. Food and Drug Administration authorized marketing of software to help medical professionals who examine body tissues (pathologists) within the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue faraway from the body). The software, called Paige Prostate, is that the first AI (AI)-based software designed to spot a neighborhood of interest on the prostate biopsy image with the v

FDA 52
article thumbnail

Which pharmaceutical drugs have the most drug patents in Ukraine?

Drug Patent Watch

This chart shows the drugs with the most patents in Ukraine. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Ukraine? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent for Allergan Holdings drug VIBERZI

Drug Patent Watch

Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 70
article thumbnail

New patent for La Jolla drug GIAPREZA

Drug Patent Watch

Annual Drug Patent Expirations for GIAPREZA Giapreza is a drug marketed by La Jolla Pharma and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for La Jolla drug GIAPREZA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 69
article thumbnail

Which pharmaceutical companies have the most SPCs in Finland?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which drugs have the most supplementary protection certificates?

Drug Patent Watch

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 69
article thumbnail

New patent for Novartis Pharms drug ENTRESTO

Drug Patent Watch

Annual Drug Patent Expirations for ENTRESTO Entresto is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Novartis Pharms drug ENTRESTO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 66